Kura Oncology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Kura Oncology, Inc. on April 23, 2015. The filing primarily addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on personnel appointments rather than financial performance results.
Material Changes
The material change reported is the appointment of Faheem Hasnain as a director of the Company, effective April 23, 2015. His term expires at the next annual meeting of stockholders. No other material changes to the company's operations or financial status are disclosed in this document.
Compensation and Governance Details
Under the Board's standard compensation policy for non-employee directors, Mr. Hasnain will receive:
- An annual cash retainer of $50,000.
- An option to purchase 30,000 shares of common stock at fair market value determined on the date of appointment.
- Vesting terms: Annual vesting over a three-year period, with acceleration in the event of a change in control during the period of Board service.
The filing confirms there are no undisclosed arrangements or transactions involving Mr. Hasnain requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the press release (Exhibit 99.1) for additional context on Mr. Hasnain's background and qualifications.
- Confirm the exact fair market value per share used for the 30,000 stock options granted on April 23, 2015.
- Review the Company's equity incentive plan to understand the specific definition of "change in control" regarding vesting acceleration.
- Check subsequent filings for the date of the next annual meeting of stockholders to determine the exact expiration of Mr. Hasnain's term.